Quantumzyme Corp. (OTC: QTZM) announced the publication of its latest research in the Journal of Molecular Graphics & Modelling, highlighting a fully computational enzyme engineering approach for sustainable drug manufacturing. The peer-reviewed study explores the use of virtual screening and computational modeling to evaluate transaminase enzyme variants used in the asymmetric synthesis of L-HPE, a chiral intermediate relevant to ACE inhibitor drug production.
Rather than relying solely on traditional experimental methods, the research employed large-scale virtual screening and ranking methodologies to assess enzyme–substrate interactions, catalytic alignment, and structural stability under defined simulation conditions. This approach enabled the identification of enzyme candidates for subsequent experimental consideration, potentially reducing the need for extensive laboratory iteration.
“Publishing this research in the Journal of Molecular Graphics & Modelling represents an important scientific milestone for Quantumzyme,” said Naveen Kulkarni, Chief Executive Officer. “This study contributes to the growing body of evidence supporting computational enzyme engineering as a complementary tool in biocatalyst development. By evaluating enzyme variants virtually prior to laboratory testing, we aim to improve research efficiency and better inform downstream validation efforts.”
The full paper is available at ScienceDirect. The publication underscores the expanding role of computational modeling in biocatalysis research, which may help reduce experimental iteration and improve prioritization of enzyme candidates for laboratory study.
Quantumzyme also provided an update on its previously announced corporate name change and trading symbol request. The company has been informed that FINRA has received all necessary information to complete its review, and the name change and new trading symbol are expected in the coming days, subject to FINRA's final approval. Upon effectiveness, the company will issue a separate announcement confirming the changes.
For more information, visit Quantumzyme's website and the company's profile at OTC Markets.
